Scinai Immunotherapeutics
SCNI
6 hedge funds and large institutions have $181K invested in Scinai Immunotherapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
301% more capital invested
Capital invested by funds: $45.2K → $181K (+$136K)
50% more funds holding
Funds holding: 4 → 6 (+2)
0.79% more ownership
Funds ownership: 0% → 0.79% (+0.79%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$29.2K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$25.2K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$4.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$7.22K |
SCNI Hedge Fund Activity: Q2 2025 in Review
6 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2025, worth a combined $181K — up 301% from $45.2K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SCNI positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $29.2K. The largest seller was UBS Group, cutting an estimated $7.22K.
- 6 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2025, up from 4 in Q1 2025.
- Funds reported $181K of Scinai Immunotherapeutics stock for Q2 2025, up 301% quarter-over-quarter.
- 3 funds opened new Scinai Immunotherapeutics positions in Q2 2025 and 0 closed out, a net change of +3 holders.
- The largest Scinai Immunotherapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $29.2K added.
- The largest Scinai Immunotherapeutics seller in Q2 2025 was UBS Group, an estimated $7.22K sold.
Based on aggregated 13F filings for Q2 2025.